leisure time -WSS

leisure time

author：explore 2025-09-05 11:32:56 - browse：8

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Alkermes shareholders re
Next article： Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

WSS

STAT readers on older presidents, polypills, Medicare, and more

A new nitrogen execution bill also undermines medical licensing

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Obesity drugs seen as possible treatment for liver disease MASH

Obesity drugs seen as possible treatment for liver disease MASH

A new nitrogen execution bill also undermines medical licensing

focus

leisure time

explore

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Medicare proposal to cover medical devices draws a mixed reaction

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Trump demands the U.S. pay no more for drugs than other countries … again

Three issues to watch in global health in 2024

Supreme Court strikes down use of affirmative action

Medicare inequities exacerbate Puerto Rico’s health disparities

Wildfire smoke exposes gaps in outdoor worker protections

Risky weight loss products often used by teens globally, per study

entertainment

Obesity drugs seen as possible treatment for liver disease MASH

Caregivers of transplant patients call for more support, training

The SUPPORT Act is critical to fighting the opioid crisis

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Risky weight loss products often used by teens globally, per study

leisure time

leisure time

leisure time

focus